cbdMD Unveils Clinical Channel to Supply Hemp CBD Under CMS BEI Incentive
cbdMD launched a clinical channel on April 1, 2026 to support CMS Innovation Center models such as ACO REACH, allowing providers to furnish hemp-derived CBD under the Substance Access Beneficiary Engagement Incentive. The channel leverages cbdMD’s OECD-standard preclinical toxicology and human randomized trial safety data for Medicare beneficiaries.
1. Clinical Channel Launch
On April 1, 2026, cbdMD activated its clinical healthcare channel to support physicians, accountable care organizations and oncology practices participating in CMS Innovation Center models, aiming to integrate hemp-derived CBD into physician-supervised, value-based care.
2. CMS Substance Access BEI Details
The Substance Access Beneficiary Engagement Incentive allows participating ACO REACH and Enhancing Oncology Model organizations to furnish eligible hemp-derived CBD to Medicare patients; CMS does not reimburse product costs or designate preferred suppliers, leaving procurement decisions to each organization.
3. Unmatched Clinical Data and Regulatory Compliance
cbdMD’s platform includes OECD-standard 90-day subchronic oral toxicity studies, IRB-approved randomized double-blind placebo-controlled human safety trials and self-affirmed GRAS regulatory dossiers, all supported by healthcare-grade supply chain traceability and certificate of analysis documentation.
4. Provider Engagement and Future Research
The company is actively engaging thousands of physicians and health systems, developing provider-focused formulations and documentation, and pursuing research partnerships with healthcare and academic institutions to generate real-world outcomes data on hemp CBD in Medicare settings.